The drug development industry has grown into a troubling duality—one characterized by scientific progress and pervasive failure. Decades of technological advancements have enabled the precise ...

Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...

This study is led by Dr. Nan Qiao (Laboratory of Health Intelligence, Huawei Cloud Computing Technologies), Dr. Hualiang Jiang (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) and ...

The Biden administration is proposing rescinding a Trump-era model that ties Medicare Part B drugs and biologicals to the lowest price that drug manufacturers receive in other wealthy countries. Known ...

Implementing the Medicare $2 drug list model would have reduced out-of-pocket spending by 63% for Part D beneficiaries in 2021. The model caps cost-sharing at $2 for a 30-day supply of 101 generic ...